150 related articles for article (PubMed ID: 38007466)
1. The survivin-ran inhibitor LLP-3 decreases oxidative phosphorylation, glycolysis and growth of neuroblastoma cells.
Galiger C; Zohora FT; Dorneburg C; Tews D; Debatin KM; Beltinger C
BMC Cancer; 2023 Nov; 23(1):1148. PubMed ID: 38007466
[TBL] [Abstract][Full Text] [Related]
2. Impairment of glioma stem cell survival and growth by a novel inhibitor for Survivin-Ran protein complex.
Guvenc H; Pavlyukov MS; Joshi K; Kurt H; Banasavadi-Siddegowda YK; Mao P; Hong C; Yamada R; Kwon CH; Bhasin D; Chettiar S; Kitange G; Park IH; Sarkaria JN; Li C; Shakhparonov MI; Nakano I
Clin Cancer Res; 2013 Feb; 19(3):631-42. PubMed ID: 23251006
[TBL] [Abstract][Full Text] [Related]
3. LDHA in Neuroblastoma Is Associated with Poor Outcome and Its Depletion Decreases Neuroblastoma Growth Independent of Aerobic Glycolysis.
Dorneburg C; Fischer M; Barth TFE; Mueller-Klieser W; Hero B; Gecht J; Carter DR; de Preter K; Mayer B; Christner L; Speleman F; Marshall GM; Debatin KM; Beltinger C
Clin Cancer Res; 2018 Nov; 24(22):5772-5783. PubMed ID: 29925504
[No Abstract] [Full Text] [Related]
4. Therapeutic targeting of YY1/MZF1 axis by MZF1-uPEP inhibits aerobic glycolysis and neuroblastoma progression.
Fang E; Wang X; Wang J; Hu A; Song H; Yang F; Li D; Xiao W; Chen Y; Guo Y; Liu Y; Li H; Huang K; Zheng L; Tong Q
Theranostics; 2020; 10(4):1555-1571. PubMed ID: 32042322
[TBL] [Abstract][Full Text] [Related]
5. FUBP1 promotes neuroblastoma proliferation via enhancing glycolysis-a new possible marker of malignancy for neuroblastoma.
Jiang P; Huang M; Qi W; Wang F; Yang T; Gao T; Luo C; Deng J; Yang Z; Zhou T; Zou Y; Gao G; Yang X
J Exp Clin Cancer Res; 2019 Sep; 38(1):400. PubMed ID: 31511046
[TBL] [Abstract][Full Text] [Related]
6. The inhibitor of apoptosis protein survivin is associated with high-risk behavior of neuroblastoma.
Azuhata T; Scott D; Takamizawa S; Wen J; Davidoff A; Fukuzawa M; Sandler A
J Pediatr Surg; 2001 Dec; 36(12):1785-91. PubMed ID: 11733907
[TBL] [Abstract][Full Text] [Related]
7. BIRC5/Survivin as a target for glycolysis inhibition in high-stage neuroblastoma.
Hagenbuchner J; Kiechl-Kohlendorfer U; Obexer P; Ausserlechner MJ
Oncogene; 2016 Apr; 35(16):2052-61. PubMed ID: 26148234
[TBL] [Abstract][Full Text] [Related]
8. Significance of survivin mRNA expression in prognosis of neuroblastoma.
Ito R; Asami S; Motohashi S; Ootsuka S; Yamaguchi Y; Chin M; Shichino H; Yoshida Y; Nemoto N; Mugishima H; Suzuki T
Biol Pharm Bull; 2005 Apr; 28(4):565-8. PubMed ID: 15802787
[TBL] [Abstract][Full Text] [Related]
9. Antiproliferative and apoptotic effect of LY2090314, a GSK-3 inhibitor, in neuroblastoma in vitro.
Kunnimalaiyaan S; Schwartz VK; Jackson IA; Clark Gamblin T; Kunnimalaiyaan M
BMC Cancer; 2018 May; 18(1):560. PubMed ID: 29751783
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Survivin Homodimerization Decreases Neuroblastoma Cell Growth.
Dorneburg C; Galiger C; Stadler GL; Westhoff MA; Rasche V; Barth TFE; Debatin KM; Beltinger C
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136322
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of neuroblastoma cell growth inhibition by CARP-1 functional mimetics.
Muthu M; Cheriyan VT; Munie S; Levi E; Frank J; Ashour AE; Singh M; Rishi AK
PLoS One; 2014; 9(7):e102567. PubMed ID: 25033461
[TBL] [Abstract][Full Text] [Related]
12. HNF4A-AS1/hnRNPU/CTCF axis as a therapeutic target for aerobic glycolysis and neuroblastoma progression.
Song H; Li D; Wang X; Fang E; Yang F; Hu A; Wang J; Guo Y; Liu Y; Li H; Chen Y; Huang K; Zheng L; Tong Q
J Hematol Oncol; 2020 Mar; 13(1):24. PubMed ID: 32216806
[TBL] [Abstract][Full Text] [Related]
13. BIRC5/Survivin enhances aerobic glycolysis and drug resistance by altered regulation of the mitochondrial fusion/fission machinery.
Hagenbuchner J; Kuznetsov AV; Obexer P; Ausserlechner MJ
Oncogene; 2013 Oct; 32(40):4748-57. PubMed ID: 23146905
[TBL] [Abstract][Full Text] [Related]
14. The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell death and inhibits tumor growth in models of neuroblastoma.
Maser T; Zagorski J; Kelly S; Ostrander A; Goodyke A; Nagulapally A; Bond J; Park Y; Saulnier Sholler G
Cancer Med; 2020 Nov; 9(21):8144-8158. PubMed ID: 33034426
[TBL] [Abstract][Full Text] [Related]
15. Survivin inhibits apoptosis induced by TRAIL, and the ratio between survivin and TRAIL receptors is predictive of recurrent disease in neuroblastoma.
Azuhata T; Scott D; Griffith TS; Miller M; Sandler AD
J Pediatr Surg; 2006 Aug; 41(8):1431-40. PubMed ID: 16863850
[TBL] [Abstract][Full Text] [Related]
16. Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma.
Kling MJ; Griggs CN; McIntyre EM; Alexander G; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
BMC Cancer; 2021 Sep; 21(1):1061. PubMed ID: 34565342
[TBL] [Abstract][Full Text] [Related]
17. The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention.
Peirce SK; Findley HW; Prince C; Dasgupta A; Cooper T; Durden DL
Cancer Chemother Pharmacol; 2011 Aug; 68(2):325-35. PubMed ID: 20972874
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of cyclin-dependent kinase 1-induced cell death in neuroblastoma cells through the microRNA-34a-MYCN-survivin pathway.
Chen Y; Tsai YH; Tseng SH
Surgery; 2013 Jan; 153(1):4-16. PubMed ID: 22703967
[TBL] [Abstract][Full Text] [Related]
19. Survivin knockdown increased anti-cancer effects of (-)-epigallocatechin-3-gallate in human malignant neuroblastoma SK-N-BE2 and SH-SY5Y cells.
Hossain MM; Banik NL; Ray SK
Exp Cell Res; 2012 Aug; 318(13):1597-610. PubMed ID: 22507272
[TBL] [Abstract][Full Text] [Related]
20. Mutant p53
Hernández-Reséndiz I; Gallardo-Pérez JC; López-Macay A; Robledo-Cadena DX; García-Villa E; Gariglio P; Saavedra E; Moreno-Sánchez R; Rodríguez-Enríquez S
J Cell Physiol; 2019 May; 234(5):5524-5536. PubMed ID: 30272821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
